Direction
Buy
Sell
Types
LMT Order
Price
QTY
Amount
--
CERE Cerevel Therapeutics Holdings
34.150-0.400-1.16%
Close
01/31 16:00 ET
High
35.260
Open
34.540
Turnover
17.64M
Low
34.050
Pre Close
34.550
Volume
510.72K
Intraday
5D
1D
1W
1M
1Q
1Y
Price Forecast
News
Comment
SG Americas Securities LLC Lowers Position in Cerevel Therapeutics Holdings, Inc. (NASDAQ:CERE)
SG Americas Securities LLC lessened its stake in Cerevel Therapeutics Holdings, Inc. (NASDAQ:CERE – Get Rating) by 48.0% during the 3rd quarter, according to the company in its most recent filing wi
State of New Jersey Common Pension Fund D Takes $2.14 Million Position in Cerevel Therapeutics Holdings, Inc. (NASDAQ:CERE)
State of New Jersey Common Pension Fund D purchased a new position in shares of Cerevel Therapeutics Holdings, Inc. (NASDAQ:CERE – Get Rating) during the third quarter, according to the company in i
Cerevel Therapeutics Holdings, Inc.'s (NASDAQ:CERE) Intrinsic Value Is Potentially 48% Above Its Share Price
Today we will run through one way of estimating the intrinsic value of Cerevel Therapeutics Holdings, Inc. (NASDAQ:CERE) by projecting its future cash flows and then discounting them to today's value.
Cerevel Therapeutics Holdings, Inc. (NASDAQ:CERE) Given Consensus Recommendation of "Moderate Buy" by Brokerages
Cerevel Therapeutics Holdings, Inc. (NASDAQ:CERE – Get Rating) has earned an average rating of "Moderate Buy" from the ten analysts that are presently covering the stock, MarketBeat reports. Two ana
Cerevel Therapeutics to Present at 41st Annual J.P. Morgan Healthcare Conference and Provide Pipeline Update
Initiated Phase 1 healthy volunteer trial to support development of emraclidine in Alzheimer's disease psychosis in Q4 2022; second potential indication as a once-daily treatment Phase 2 proof-of-concept darigabat panic
Cerevel Therapeutics to Present at the 41st Annual J.P. Morgan Healthcare Conference
CAMBRIDGE, Mass., Jan. 04, 2023 (GLOBE NEWSWIRE) -- Cerevel Therapeutics, (NASDAQ:CERE), a company dedicated to unraveling the mysteries of the brain to treat neuroscience diseases, today announced that chairperson and
Are Cerevel Therapeutics Holdings, Inc. (NASDAQ:CERE) Investors Paying Above The Intrinsic Value?
Cerevel Therapeutics (NASDAQ:CERE) Trading Down 3.6%
Shares of Cerevel Therapeutics Holdings, Inc. (NASDAQ:CERE – Get Rating) dropped 3.6% during mid-day trading on Friday . The company traded as low as $30.26 and last traded at $30.31. Approximately 1
Cerevel Therapeutics (NASDAQ:CERE) Price Target Raised to $46.00 at Cantor Fitzgerald
Cerevel Therapeutics (NASDAQ:CERE – Get Rating) had its price target lifted by Cantor Fitzgerald from $41.00 to $46.00 in a report issued on Tuesday, The Fly reports. Other equities research analysts
Cerevel Therapeutics Holdings, Inc. (NASDAQ:CERE) Receives Average Rating of "Moderate Buy" From Analysts
Shares of Cerevel Therapeutics Holdings, Inc. (NASDAQ:CERE – Get Rating) have been assigned an average recommendation of "Moderate Buy" from the ten ratings firms that are covering the stock, Market
Company Overview
More
Cerevel Therapeutics Holdings, Inc. engages in the discovery and development of new therapies for neuroscience diseases. The firm's portfolio focuses on diseases such as schizophrenia, epilepsy, and Parkinson's disease. Its product candidates include CVL-231, Darigabat, Tavapadon, CVL-871, and CVL-936. The company was founded in 2018 and is headquartered in Cambridge, MA.
CEO： Dr. N. Anthony Coles, M.D.
Market： NASDAQ
Listing Date： 06/05/2020
Paper Trade
More
Hot List
TradeSearchNews
SymbolLatest price%Chg
Loading...
Watchlist
No Stock Yet